ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer
(1994) In Cancer Letters 81(2). p.137-144- Abstract
- Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence... (More)
- Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1107793
- author
- Borg, Åke LU ; Baldetorp, Bo LU ; Fernö, Mårten LU ; Killander, Dick LU ; Olsson, Håkan LU ; Ryden, Stefan and Sigurdsson, Helgi
- organization
- publishing date
- 1994
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- ERBB2, HER-2/neu, Gene amplification, Breast cancer, Adjuvant tamoxifen, Therapy resistance
- in
- Cancer Letters
- volume
- 81
- issue
- 2
- pages
- 137 - 144
- publisher
- Elsevier
- external identifiers
-
- pmid:7912163
- scopus:0028360192
- ISSN
- 1872-7980
- DOI
- 10.1016/0304-3835(94)90194-5
- language
- English
- LU publication?
- yes
- id
- 2fef2982-b3de-4e06-beae-97042cee2e70 (old id 1107793)
- date added to LUP
- 2016-04-01 16:23:46
- date last changed
- 2021-10-10 03:01:57
@article{2fef2982-b3de-4e06-beae-97042cee2e70, abstract = {{Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.}}, author = {{Borg, Åke and Baldetorp, Bo and Fernö, Mårten and Killander, Dick and Olsson, Håkan and Ryden, Stefan and Sigurdsson, Helgi}}, issn = {{1872-7980}}, keywords = {{ERBB2; HER-2/neu; Gene amplification; Breast cancer; Adjuvant tamoxifen; Therapy resistance}}, language = {{eng}}, number = {{2}}, pages = {{137--144}}, publisher = {{Elsevier}}, series = {{Cancer Letters}}, title = {{ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer}}, url = {{http://dx.doi.org/10.1016/0304-3835(94)90194-5}}, doi = {{10.1016/0304-3835(94)90194-5}}, volume = {{81}}, year = {{1994}}, }